Pediatric ovarian dysgerminoma

Summary

Pediatric ovarian dysgerminoma (MONDO:0004193) is a disease. A subtype of dysgerminoma of ovary — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pediatric ovarian dysgerminoma
Mondo ID	MONDO:0004193
DOID	DOID:7340
NCIT	C6550
UMLS	C1332988
MedGen	272465
GARD	0023869
Is cancer (heuristic)	no

Also known as: childhood dysgerminoma · childhood dysgerminoma of ovary · childhood ovarian dysgerminoma · childhood ovarian germinomatous germ cell tumor · childhood ovarian germinomatous germ cell tumour · dysgerminoma of ovary of childhood · paediatric dysgerminoma of ovary · pediatric dysgerminoma of ovary

Disease family

This is a subtype of dysgerminoma of ovary. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant germ cell tumor › dysgerminoma › dysgerminoma of ovary › pediatric ovarian dysgerminoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.